Virtual reality to improve comfort for adults with hematologic cancer in hospital
Official title: An Open-Label, Multicenter, Randomized Controlled Trial to Evaluate the Effect of a Non-Pharmacological Virtual Reality Intervention on Comfort in Hospitalized Hematology Patients
Run by Fundación para la Investigación del Hospital Clínico de Valencia · NCT07894601 · Data updated 2026-11-12
Researchers are testing whether short VR experiences can help comfort and mood for adults with blood cancers who are staying in the hospital for at least 15 days.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 145 (estimated) |
| Sponsor | Fundación para la Investigación del Hospital Clínico de Valencia Academic / other |
| Locations | 2 sites (Valencia, Valencia and 1 other locations) |
| Status | Recruiting |
| Started | October 26, 2026 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2029 |
| Registry record updated | November 2, 2026 |
| Trial ID | NCT07894601 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with a hematologic malignancy who are hospitalized for at least 15 consecutive days.
✕Probably not a fit
Patients who do not experience comfort or quality-of-life improvements from VR or who cannot tolerate VR due to adverse effects may receive no benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter, randomized, open-label study compares a 15-minute immersive VR intervention using Meta Quest 3S headsets to standard care in hospitalized adults with hematologic malignancies. Participants receive VR sessions on days 5, 8, 15, and 22, with comfort and quality of life assessed on days 5 and 22, and immediate effects monitored around each session. Primary outcomes include overall comfort and health-related quality of life, while safety measures track potential adverse effects from VR. The study is conducted in Valencia, Spain, enrolling about 145 participants, with data collection planned to conclude in December 2028.
Why it matters
Potential benefit: If successful, VR could provide a nonpharmacologic way to improve comfort and well-being during hospitalization for hematologic cancer.
How similar studies have gone: Previous studies with similar VR approaches in hospitalized patients have shown promising improvements in comfort and mood, supporting further evaluation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and female patients, aged 18 or more and different racial backgrounds. * Diagnosed with a hematological condition. * Hospital stay of 15 days or longer to receive treatment for a diagnosed hematological malignancy. Exclusion Criteria: * Language barriers or physical and/or cognitive impairments that prevent patients from understanding the intervention or completing the study assessment tools. * History of photosensitive epilepsy and/or intolerance to virtual reality. * Failure to provide informed consent or withdrawal of informed consent.
Where it's running
-
Instituto de Investigacion Sanitaria INCLIVA
Valencia, Valencia, Spain Recruiting -
Consorcio Hospital General Universitario de Valencia
Valencia, Valencia, Spain Recruiting
Study contacts
- Study coordinator: Julia Carrió Fito RN, MSc, PhD(c), Nurse
- Email: julia.carrio@uv.es
- Phone: +34667229297
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Genetics of Blood Cancers in the U.S. population
This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.
-
Venetoclax added to reduced-intensity conditioning for combined stem cell and kidney transplant
This trial tests whether adding venetoclax to a reduced-intensity conditioning regimen is safe for adults with blood cancers who are receiving a combined stem cell and kidney transplant from a matched or partially matched donor.
-
Using exercise and nutrition to reduce CAR‑T neurotoxicity in adults with blood cancers
This test will try whether a structured exercise program alone or combined with nutrition advice can lower the risk or severity of neurotoxicity after CAR‑T therapy in adults (18–80) with hematologic cancer.
-
Florida ASCENT Program
This project will test whether combining the MyCarePulse EHR platform with ASCENT patient navigators helps adults with recent cancer diagnoses in Florida improve food security, diet quality, and confidence in healthy eating compared with standard care.
-
18F-G1 PET/CT to see early immunotherapy response in solid tumors and blood cancers
We are testing if the 18F-G1 PET/CT scan can help tell early on whether people with solid tumors or blood cancers will respond to immunotherapy.
-
Monitoring complications during immunotherapy for blood cancers
This study is testing a new way to keep an eye on patients with blood cancers during immunotherapy to catch problems early and improve their safety and care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.